US Stock MarketDetailed Quotes
PHIO Phio Pharmaceuticals
- 1.7600
- +0.0200+1.15%
Close Dec 20 16:00 ET
- 1.6601
- -0.0999-5.68%
Post 19:57 ET
2.63MMarket Cap-0.18P/E (TTM)
1.8100High1.5700Low348.38KVolume1.6500Open1.7400Pre Close587.78KTurnover23.40%Turnover RatioLossP/E (Static)1.49MShares10.350052wk High0.53P/B2.62MFloat Cap1.530052wk Low--Dividend TTM1.49MShs Float3118.4994Historical High--Div YieldTTM13.79%Amplitude1.5300Historical Low1.6870Avg Price1Lot Size
Phio Pharmaceuticals Stock Forum
Sign in to post a comment
$Phio Pharmaceuticals (PHIO.US)$
In a concurrent private placement to the same institutional investors, we are also issuing unregistered warrants to purchase up to 437,192 shares of Common Stock (the “Private Warrants”). For each share of Common Stock issued in this registered offering, an accompanying Private Warrant will be issued to the purchaser thereof. Each Private Warrant will be exercisable for one share of Common Stock at an exercise price of $2.51 per share, will be immediately exerc...
In a concurrent private placement to the same institutional investors, we are also issuing unregistered warrants to purchase up to 437,192 shares of Common Stock (the “Private Warrants”). For each share of Common Stock issued in this registered offering, an accompanying Private Warrant will be issued to the purchaser thereof. Each Private Warrant will be exercisable for one share of Common Stock at an exercise price of $2.51 per share, will be immediately exerc...
1
$Phio Pharmaceuticals (PHIO.US)$
Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Thursday, 19th December at 2:28 pm
Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced t...
Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Thursday, 19th December at 2:28 pm
Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced t...
3
6
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Phio Pharmaceuticals (PHIO.US)$ Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1B Trial To Evaluate The Safety And Tolerability Of PH-762 For Stages 1, 2, And 4 Cutaneous Squamous Cell Carcinoma, Stage 4 Melanoma, And Stage 4 Merkel Cell Carcinoma
2
4
$Phio Pharmaceuticals (PHIO.US)$
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
Thursday, 19th December at 7:45 am
Phio's Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration
Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage bio...
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
Thursday, 19th December at 7:45 am
Phio's Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration
Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage bio...
$Phio Pharmaceuticals (PHIO.US)$
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Tuesday, 3rd December at 7:45 am
Registration Link for Presentation and live Q&A to take place, Tuesday, December 10, 2024 at 12:00 pm EST
Marlborough, Massachusetts--(Newsfile Corp. - December 3, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silenci...
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Tuesday, 3rd December at 7:45 am
Registration Link for Presentation and live Q&A to take place, Tuesday, December 10, 2024 at 12:00 pm EST
Marlborough, Massachusetts--(Newsfile Corp. - December 3, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silenci...
1
$Phio Pharmaceuticals (PHIO.US)$
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
Phio Pharmaceuticals (NASDAQ: PHIO) has completed enrollment for the second cohort in its PH-762 Phase 1b dose-escalating clinical trial and added a sixth clinical site in San Diego. New data from the trial shows promising results, with one patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tu...
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
Phio Pharmaceuticals (NASDAQ: PHIO) has completed enrollment for the second cohort in its PH-762 Phase 1b dose-escalating clinical trial and added a sixth clinical site in San Diego. New data from the trial shows promising results, with one patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tu...
$Phio Pharmaceuticals (PHIO.US)$
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Phio Pharmaceuticals (NASDAQ: PHIO) announced new clinical data presentation from its ongoing Phase 1b trial at the 39th Annual SITC Meeting. The trial evaluates PH-762 through intratumoral injection in patients with various skin cancers. Results show the treatment has been well-tolerated with no adverse events across five patient...
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Phio Pharmaceuticals (NASDAQ: PHIO) announced new clinical data presentation from its ongoing Phase 1b trial at the 39th Annual SITC Meeting. The trial evaluates PH-762 through intratumoral injection in patients with various skin cancers. Results show the treatment has been well-tolerated with no adverse events across five patient...
$Allarity Therapeutics (ALLR.US)$ $PainReform (PRFX.US)$ $Helius Medical Technologies (HSDT.US)$ $Salarius Pharmaceuticals (SLRX.US)$ $Phio Pharmaceuticals (PHIO.US)$ $Entero Therapeutics (ENTO.US)$ $Vaccinex (VCNX.US)$ $Bone Biologics (BBLG.US)$ $Wang & Lee Group (WLGS.US)$ $Nuburu (BURU.US)$ $Quoin Pharmaceuticals (QNRX.US)$
1
3
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
timmyssonoma : is this good or bad news the offering is above the prices it is now but it's a dullsion right?